BRST5:Inflammatory myofibroblastic tumour: Difference between revisions
| [checked revision] | [checked revision] |
Kgeiersbach (talk | contribs) Updated for template change |
Kgeiersbach (talk | contribs) No edit summary |
||
| Line 58: | Line 58: | ||
!Clinical Relevance Details/Other Notes | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
|''ALK''||''TPM3''::''ALK, TPM4''::''ALK, EML4''::''ALK'', ''RANBP2''::''ALK, CLTC''::''ALK'', and others||Fusions result in constitutive activation of the ''ALK'' tyrosine kinase. The most common ''ALK'' fusion breakpoints occur in intron 19 of ''ALK''. At the transcript level, a variable (5’) partner gene is fused to 3’ ''ALK'' at exon 20. At the DNA level, alternative ''ALK'' breakpoints in rare cases occur upstream of exon 19, most commonly in intron 18.|| | |''ALK''||''TPM3''::''ALK, TPM4''::''ALK, EML4''::''ALK'', ''RANBP2''::''ALK, CLTC''::''ALK'', and others||Fusions result in constitutive activation of the ''ALK'' tyrosine kinase. The most common ''ALK'' fusion breakpoints occur in intron 19 of ''ALK''. At the transcript level, a variable (5’) partner gene is fused to 3’ ''ALK'' at exon 20. At the DNA level, alternative ''ALK'' breakpoints in rare cases occur upstream of exon 19, most commonly in intron 18.||Rearrangements of ''ALK'' gene locus at 2p23 | ||
| | |Common | ||
|D, T | |D, T | ||
|<span class="blue-text">EXAMPLE:</span> Yes (WHO, NCCN) | |<span class="blue-text">EXAMPLE:</span> Yes (WHO, NCCN) | ||
| Line 67: | Line 67: | ||
|''TFG''::''ROS1'', ''YWHAE''::''ROS1'', and others | |''TFG''::''ROS1'', ''YWHAE''::''ROS1'', and others | ||
|Fusions result in constitutive activation of the ''ROS1'' tyrosine kinase. Most common ''ROS1'' breakpoints occur in intron 35; at the transcript level, various 5' partner genes are fused to exon 36 of ''ROS1''. | |Fusions result in constitutive activation of the ''ROS1'' tyrosine kinase. Most common ''ROS1'' breakpoints occur in intron 35; at the transcript level, various 5' partner genes are fused to exon 36 of ''ROS1''. | ||
| | |Rearrangements of ''ROS1'' gene locus at 6q22 | ||
| | |Recurrent | ||
|D, T | |D, T | ||
| | | | ||
| Line 75: | Line 75: | ||
|''NTRK3'' | |''NTRK3'' | ||
|''ETV6''::''NTRK3'' and others | |''ETV6''::''NTRK3'' and others | ||
|Fusions result in constitutive activation of the ''NTRK3'' tyrosine kinase. | |Fusions result in constitutive activation of the ''NTRK3'' tyrosine kinase. | ||
|Rearrangements of ''NTRK3'' gene locus at 15q25. Classically, the reciprocal translocation t(12;15)(p13;q25) is associated with ''ETV6''::''NTRK3'' rearrangement. | |||
|Recurrent | |||
|D, T | |||
| | | | ||
| | | | ||
|- | |||
|''PDGFRB'' | |||
|''NAB2''::''PDGFRB'' and others | |||
|Fusions result in constitutive activation of the ''PDGFRB'' tyrosine kinase. | |||
|Rearrangements of the ''PDGFRB'' gene locus at 5q32. | |||
|Rare | |||
|D, T | |D, T | ||
| | | | ||
| Line 84: | Line 93: | ||
|''NTRK1'' | |''NTRK1'' | ||
| | | | ||
|Fusions result in constitutive activation of the ''NTRK1'' tyrosine kinase. | |Fusions result in constitutive activation of the ''NTRK1'' tyrosine kinase. | ||
| | |Rearrangements of the ''NTRK1'' gene locus at 1q23. | ||
| | |Rare | ||
|D, T | |D, T | ||
| | | | ||
| | | | ||
|- | |- | ||
|'' | |''RET'' | ||
| | | | ||
|Fusions result in constitutive activation of the ''RET'' tyrosine kinase. | |||
|Rearrangements of the ''RET'' gene locus at 10q11. | |||
|Rare | |||
|D, T | |D, T | ||
| | | | ||
| Line 199: | Line 208: | ||
Prior Author(s): | Prior Author(s): | ||
<references /> | |||